Compare VanEck Rare Earth/Strategic Metals (REMX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Rare Earth/Strategic Metals vs Tango Therapeutics Inc. — how do they compare? VanEck Rare Earth/Strategic Metals trades at $54.5 (market cap $1.64B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 2.3× VanEck Rare Earth/Strategic Metals's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Rare Earth/Strategic Metals for 52 Days and Tango Therapeutics Inc. for 0 Days on average.
| REMX | TNGX | |
|---|---|---|
Market Cap | $1.64B | $3.75B |
Volume | 710,568 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $109.53 | $32.90 |
52-Week Low | $55.78 | $7.50 |
Typical Hold Time | 52 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $57.45, down 1.25% amid bearish technical signals with moving averages indicating strong selling pressure. The ETF provides exposure to 38 global rare earth companies but faces high volatility and China concentration risks. Recent institutional activity includes Bank of America increasing its position by 72.1% in Q2 2026, while geopolitical developments around critical minerals supply chains continue to influence sentiment.
The outlook remains challenged by technical weakness and sector volatility, though oversold RSI readings suggest potential near-term bounce. Long-term prospects hinge on U.S. supply chain development and China export policies, but the ETF's 50% annualized volatility makes it unsuitable for conservative investors. Strategic importance of rare earths supports thematic interest despite execution risks.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
